Search

Displaying results 2801 - 2810 of 10000 in total
  1. Drug

    Ioxilan

    go.drugbank.com/drugs/DB09135
    ApprovedWithdrawn

    Ioxilan is a tri-iodinated diagnostic contrast agent.

    Categories: Compounds used in a research, industrial, or household setting, X-Ray Contrast ActivitySynonyms: N-(2,3-dihydroxypropyl)-N’-(2- hydroxyethyl)-5-[N-(2,3-dihydroxypropyl) acetamido]-2,4,6-triiodoisophthal-amide
  2. Drug

    Ginseng

    go.drugbank.com/drugs/DB01404
    ApprovedInvestigationalNutraceutical

    Ginseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties

    Mixtures: BEDOYECTA + G, GINSENG-E CAPSULEProducts: Dendropanax M, SINGISO 101 (0.8g)
  3. Drug

    LSZ-102

    go.drugbank.com/drugs/DB15362
    Investigational

    LSZ-102 is under investigation in clinical trial NCT02734615 (Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers).

    Categories: Heterocyclic Compounds, 1-Ring
  4. Indication

    Tremor

    go.drugbank.com/conditions/DBCOND0003658
    Drugs: Bornaprine · Diazepam
    Synonyms: Has a tremor, (Has a tremor) or (tremor symptom) or (shaking)
  5. Drug

    EVT-101

    go.drugbank.com/drugs/DB05956
    Investigational

    Categories: Heterocyclic Compounds, 1-Ring
  6. Drug

    Imidafenacin

    go.drugbank.com/drugs/DB09262
    Investigational

    It is marketed in Japan under the tradenames Staybla by Ono Pharmaceutical and Uritos by Kyojin Pharmaceutical. … Imidafenacin is an antispasmodic agent with anticholinergic effects. It antagonizes muscarinic receptors in the bladder to reduce the frequency of urination in the treatment of overactive bladder.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: URITOS (TABLETS 0.1 MG), URITOS TABLETS 0.1 MG
  7. Target

    SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5

    go.drugbank.com/bio_entities/BE0004581
    TargetHumans

    Essential component of the WICH-5 ISWI chromatin-remodeling complex (also called the WICH complex), a chromatin-remodeling complex that mobilizes nucleosomes and reconfigures irregular chromatin to a regular … Within the B-WICH complex has a role in RNA polymerase III transcription (PubMed:16603771).

    Polypeptides: SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5
  8. Target

    SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2

    go.drugbank.com/bio_entities/BE0013298
    TargetHumans

    During neural development a switch from a stem/progenitor to a postmitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. … The nBAF complex along with CREST plays a role regulating the activity of genes essential for dendrite growth (By similarity)

    Polypeptides: SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2
  9. Drug

    Pine tar

    go.drugbank.com/drugs/DB15840
    ApprovedWithdrawn

    Products: WILKINSON POMAD %12.5 100 GR, Psoriasol 500
  10. Drug

    Levodopa

    go.drugbank.com/drugs/DB01235
    ApprovedInvestigational

    The first developed drug product that was approved by the FDA was a levodopa and carbidopa combined product called Sinemet that was approved on May 2, 1975[A177781,L6133]. … Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label].

    Mixtures: CARBIDOPA X 25 MG Y LEVODOPA X 250 MG, CARBIDOPA X 25 MG Y LEVODOPA X 250 MGSynonyms: 3-Hydroxy-L-tyrosine, L-DOPA